Validation of a genotyping technique for a surrogate marker of HLA-B58:01 for allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in the Japanese population
Drug Metabolism and Pharmacokinetics · 2023
DOI: 10.1016/j.dmpk.2023.100495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2023. Verfasst von Eri Tsukagoshi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, 210-9501, Japan. Hauptthemen laut MEDLINE: Allopurinol, Stevens-Johnson Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe cutaneous adverse drug reactions. Certain human leukocyte antigen (HLA) types have been associated with SJS/TEN onset, e.g., HLA-B∗58:01 with allopurinol-induced SJS/TEN, but HLA typing is time-consuming and expensive; thus, it is not commonly used in clinical situations. In the previous work, we demonstrated that the single-nucleotide polymorphisms (SNP) rs9263726 was in absolute linkage disequilibrium with HLA-B∗58:01 in the Japanese population, and can be used as a surrogate marker for the HLA. Here, we developed a new genotyping method for the surrogate SNP using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS) technique and performed an analytical validation. The results of genotyping rs9263726 using STH-PAS correlated well with those obtained using the TaqMan SNP Genotyping Assay for 15 HLA-B∗58:01-positive and 13 HLA-B∗58:01-negative patients (analytical sensitivity and specificity were both 100%). Additionally, at least 1.11 ng of genomic DNA was sufficient to digitally and manually detect positive signals on the strip. Robustness studies showed that the annealing temperature (66 °C) was the most important condition related to reliable results. Collectively, we developed an STH-PAS method that can rapidly and easily detect rs9263726 for predicting SJS/TEN onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, 210-9501, Japan.
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, 210-9501, Japan. Electronic address: ryosnak@nihs.go.jp.
- Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, 610-0395, Japan.
- Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan; Research Center for Innovations in Next-Generation Medicine, Tohoku U…
- Department of Dermatology, School of Medicine, Nara Medical University, Kashihara, 634-8522, Japan.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Tsukagoshi, E., Nakamura, R., Tanaka, Y., Maekawa, K., Hiratsuka, M., Asada, H., & Saito, Y. (2023). Validation of a genotyping technique for a surrogate marker of HLA-B58:01 for allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in the Japanese population. Drug Metabolism and Pharmacokinetics. https://doi.org/10.1016/j.dmpk.2023.100495
Vancouver
Tsukagoshi E, Nakamura R, Tanaka Y, Maekawa K, Hiratsuka M, Asada H, et al. Validation of a genotyping technique for a surrogate marker of HLA-B58:01 for allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in the Japanese population. Drug Metabolism and Pharmacokinetics. 2023. doi:10.1016/j.dmpk.2023.100495
BibTeX
@article{Tsukagoshi2023,
author = {Tsukagoshi, Eri and Nakamura, Ryosuke and Tanaka, Yoichi and Maekawa, Keiko and Hiratsuka, Masahiro and Asada, Hideo and Saito, Yoshiro},
title = {Validation of a genotyping technique for a surrogate marker of HLA-B58:01 for allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in the Japanese population},
journal = {Drug Metabolism and Pharmacokinetics},
year = {2023},
doi = {10.1016/j.dmpk.2023.100495}
}
EUVIMED